IQVIA (NYSE:IQV - Free Report) had its target price decreased by Truist Financial from $263.00 to $216.00 in a research report released on Thursday morning,Benzinga reports. Truist Financial currently has a buy rating on the medical research company's stock.
A number of other analysts have also commented on the stock. StockNews.com lowered shares of IQVIA from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th. UBS Group decreased their price objective on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Morgan Stanley raised their target price on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They issued an "overweight" rating and a $250.00 price target for the company. Finally, Citigroup reduced their price objective on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Six investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and an average target price of $241.50.
View Our Latest Report on IQVIA
IQVIA Trading Down 1.1 %
IQV stock traded down $1.73 during trading on Thursday, hitting $149.19. The company had a trading volume of 475,645 shares, compared to its average volume of 1,663,360. The firm has a 50-day moving average price of $181.23 and a 200-day moving average price of $198.80. IQVIA has a 12 month low of $135.97 and a 12 month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market cap of $26.30 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 1.99 and a beta of 1.46.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts predict that IQVIA will post 10.84 earnings per share for the current year.
Institutional Trading of IQVIA
Hedge funds and other institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. raised its stake in shares of IQVIA by 55.6% during the 1st quarter. Assenagon Asset Management S.A. now owns 397,772 shares of the medical research company's stock worth $70,127,000 after purchasing an additional 142,170 shares in the last quarter. Terra Alpha Investments LLC lifted its stake in IQVIA by 4.8% in the first quarter. Terra Alpha Investments LLC now owns 7,644 shares of the medical research company's stock valued at $1,348,000 after acquiring an additional 347 shares during the last quarter. GAMMA Investing LLC grew its position in shares of IQVIA by 56.3% in the 1st quarter. GAMMA Investing LLC now owns 2,197 shares of the medical research company's stock valued at $387,000 after acquiring an additional 791 shares during the period. Harbor Capital Advisors Inc. bought a new stake in shares of IQVIA in the 1st quarter valued at about $482,000. Finally, Bruce G. Allen Investments LLC lifted its stake in IQVIA by 178.4% in the 1st quarter. Bruce G. Allen Investments LLC now owns 323 shares of the medical research company's stock valued at $57,000 after purchasing an additional 207 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
About IQVIA
(
Get Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
